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Case Number 7
Beta thalassemia major with pulmonary hypertension 
Christian Schembri & Gabriel Gauci
Reviewed by: Dr. Daniel Micallef
Case summary:
Demographic details:
Mr. IB, 29
Referred to: A&E
Mr. IB, a 29-year-old gentleman, who is a known case of beta thalassemia major, was referred from 
the emergency department following an episode of lethargy, cough, exertional dyspnoea and dyspepsia. 
During his stay, a number of investigations were carried out and the patient was diagnosed with 
pulmonary hypertension with a mean pulmonary artery pressure of 90-100mmHg – a complication of 
beta thalassemia.
This is the only reported case in Malta.
Following the diagnosis, the patient was given a number of drugs (see below) to control his symptoms.
Presenting complaint:
Dyspepsia
Exertional dyspnoea
Cough
Lethargy
History of presenting complaint:
The patient was admitted with a presenting complaint of dyspnoea on exertion, lethargy and cough 
together with dyspepsia. There was no documented history of fever or recent travel.
Past medical history:
Patient was known to suffer from thalassemia major and underwent splenectomy 20 years ago and as a 
result, the patient is chronically jaundiced. Has a history of blood transfusions as part of treatment for the 
symptoms of beta thalassemia major. 
Beta thalassemia major with iron overload (markedly increased serum ferritin).  
Decreased levels of testosterone in setting of low levels of LH and FSH (hypogoandotrophic 
hypogonadism), a direct effect of iron overload which deposits in the pituitary gland. Bilateral testicular 
biopsy had shown a reduced number of germinal cells, with an increased number of Sertoli cells. An MRI 
of pituitary showed rather small pituitary gland, poor enhancement but no lesions and a central pituitary 
stalk.
Hepatomegaly was confirmed by ultrasound, in which the liver had a hyperechoic homogeneous structure.
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Past surgical history
Splenectomy during childhood.
Drug history:
Drug Name Dosage Frequency Type Reason
Deferasirox (Exjade) 1750mg Daily Tablet for oral 
suspension
Iron chelator to reduce    
further iron overload
Phenoxymethylpenicillin 
(Penicillin V)
250mg QDS Oral tablet To prevent infection        
following splenectomy 
Folic acid 5mg Daily Oral tablet For maintenance of 
normal erythropoiesis, as 
erythropoiesis increases 
due to underlying beta 
thalassemia major
The patient has no known drug allergies (NKDA).
Family history: 
The patient has a family history of beta thalassemia. Both parents are known to be carriers of the condition. 
His sister was also affected and died of the condition. 
Social history: 
The patient is married and currently unemployed. He tends to binge drink on weekends and smokes a 
packet of cigarettes a day. 
Systemic inquiry:  
• General Health: Chronic jaundice and lethargy
• Cardiovascular System: Concentric left ventricular hypertrophy, inferior vena cava dilated, dilated 
right chambers
• Respiratory System: High raised pulmonary arterial pressure, around 90-100mmHg. Right 
Ventricular Outflow Tract (RVOT) and Main Pulmonary Artery (MPA) dilated. Exertional 
dyspnoea, cough.
• Gastrointestinal Tract: Indigestion, dyspepsia
• Genitourinary System: Nil to note 
• Central Nervous System: Nil to note
• Musculoskeletal System: Nil to note
• Endocrine System: Iron overload
Discussion of results of general and specific examinations: 
On admission to A&E:
Following admission, the following examinations were performed: 
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Exam    Result
Pulse    110bpm
SpO2    100% on oxygen
Blood pressure  125/76 mmHg
Temperature   Afebrile
CVS sounds   S1 + S2 + 0, raised jugular venous pressure (JVP)
Chest    Clear
Abdomen   Soft and non-tender
ECG    T wave inversion across the anterior leads which was previously present
Chest X-Ray   Cardiomegaly, which was not present on previous chest X-Rays,      
    pericardial effusion with pleural effusion.
Arterial Blood Gases   •pO2: 47.9 mmHg
(ABG)    •pCO2: 34.6 mmHg
Blood analysis  •Troponin normal
    •Positive D-dimer levels
    •Low fibrinogen levels
    •Lactate: 4.6
    •WBC count 140.70x109/L 
CT Pulmonary Angiogram  CTPA showed cardiomegaly but excluded pulmonary embolism.
(CTPA)  
Further specific tests following ward admission:
Exam    Result
Plethysomgraphy   Performed prior to starting treatment for pulmonary hypertension
Chest X-ray revealed a pericardial effusion with pleural effusion. Further examination confirmed free 
fluid in the abdomen and pelvis together with a few stones in the gall bladder but a normal common bile 
duct (CBD). Right heart studies were also performed by catheterisation. 
Patient also showed persistently increased INR and deranged liver enzymes. 
Differential diagnosis:
• Acute haemolytic state, probably secondary to infection, possibly with Disseminated Intravascular 
Coagulation (DIC).
• Dyspnoea on admission: 
  a. Pulmonary embolism – excluded via CTPA.
  b. Chest infection – which was also supported by the high WBC count.
  c. Pulmonary hypertension which was confirmed on investigation.
• Spontaneous increase in INR – probably due to liver dysfunction and possibly DIC secondary to 
infection.
Diagnostic procedures:
Laboratory Exams:
Test: Arterial Blood Gases (ABG)
Justification for test: To measure the partial pressures of Oxygen (pO2) and Carbon Dioxide (pCO2).
Result: pO2 was 49.7mmHg (75-100mmHg), pCO2 was 34.6mmHg (35-45mmHg)
Conclusion: Low pO2 levels and hence hypoxemia.
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Test: Troponin
Justification for test: Troponin used as a marker of heart tissue damage. Beta-thalassemia associated with 
increased risk of heart tissue damage and cardiovascular diseases.
Result: Normal troponin levels.
Conclusion: Myocardial infarction is excluded.
Test: D-dimer (Fibrin degradation fragment)
Justification for test: Suspected pulmonary embolism; to rule out the presence of a thrombus. Also due 
to suspected DIC.
Result: Positive D-dimer levels indicative of high levels of fibrin degradation products.
Conclusion: Positive D-dimer levels correspond to possible pulmonary embolism and DIC.
Test: Fibrinogen (Factor I)
Justification for test: Complimentary test to D-Dimer to help with diagnosis of DIC. Test for fibrinogen 
activity.
Result: Low fibrinogen levels.
Conclusion: Low fibrinogen levels suggestive of increased fibrinogen consumption. Possible DIC.
Instrumental Exam:
Test: Chest X-Ray (CXR)
Justification for test: To identify consolidation, pneumothorax or signs of heart failure.
Result: CXR showed cardiomegaly that was not present on previous CXRs. 
Conclusion: Cardiomegaly and query of pericardial effusion.
Test: CT Pulmonary Angiogram (CTPA)
Justification for test: To produce an image of the pulmonary arterial supply using computed tomography 
and intravenous contrast medium.
Result: CTPA confirmed cardiomegaly but did not show signs of pulmonary embolism. 
Conclusion: Pulmonary embolism excluded.
Test: Right Heart Studies/Catheterisation 
Justification for test: To determine and assess the function of the heart and the pulmonary arterial pressure.
Result: Right heart studies showed an elevated pulmonary arterial pressure of 90-100mmHg. 
Conclusion: Confirmed pulmonary hypertension.
 Therapy:
Drugs:
The patient was transfused two units of packed red blood cells (PRC) in view of a low level of haemoglobin 
(Hb) of 6.6 g/L (13-18 g/L).
Drug Dosage Frequency Formulation Reason
Meropenem 1mg Every 8 
hours
Infusion To treat possible infection 
in lungs (pneumonia)
Deferasirox (Exjade) 1750mg OD, 
indefinite
Tablet for oral 
suspension
To treat the iron overload
56
Chorionic Gonadotropin 
(Gonasi®)
5000 I.U. Three times 
a week 
(T.I.W.), 
indefinite
Subcutaneous 
injection
To stimulate the Leydig 
cells in the testes hence 
stimulating production of 
testosterone
Bumetanide 1mg OD for 6 
days
Oral tablet Loop diuretic to treat the 
heart failure
Phenoxymethylpenicillin 
(Penicillin V) 
500mg OD, 
indefinite
Oral tablet To prevent infection 
following splenectomy
Co-amoxiclav – 
following meropenem 
administration
375mg TDS for 3 
days
Oral tablet To treat possible 
pneumonia
Amoxillin – following 
meropenem administration
250mg TDS for 3 
days
Oral tablet To treat possible 
pneumonia
Diagnosis:
Being a known case of beta thalassemia, the presenting complaint of dyspnoea cough and lethargy indicated 
a complication of the condition. With the D-dimer being positive, the possibility of pulmonary embolism 
and DIC were considered. With the exclusion of pulmonary embolism using CTPA, it was concluded 
that the patient was experiencing complications of beta thalassemia leading to pulmonary hypertension, 
possible pneumonia and DIC. The patient was therefore administered intravenous antibiotics to treat the 
possible pneumonia and a loop diuretic to control the symptoms of pulmonary hypertension. 
Final treatment and follow ups:
Following recovery after treatment for pulmonary hypertension, pneumonia and DIC, the patient was 
advised to stop smoking, stop binge drinking and reduce exertion. A follow-up appointment for right 
heart studies was given to the patient. A renal function test (urea, electrolytes, creatinine) to look for 
adverse effects of bumetanide (low sodium or rise in creatinine) was booked.
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Fact Box 7:
Title: Beta Thalassemia Major (with pulmonary hypertension)
Pathophysiology:  
Beta Thalassemia is a group of hereditary disorders of the blood which are characterised by aberrant 
expression of the beta haemoglobin genes, with Beta Thalassemia Major generally involving homozygosity 
for beta-zero (beta0) or compound heterozygosity for beta-plus (beta+) 1. As a result of the mutations 
there is reduced synthesis of the beta chains of haemoglobin which leads to reduced levels of functional 
haemoglobin in the red blood cells, hence resulting in anaemia due to reduced oxygen carrying capacity 
of the red blood cells 1. Because of this, the patient must undergo regular blood transfusions so that correct 
levels of functional haemoglobin are maintained in the blood.  However, repeated blood transfusions lead 
to iron overload and eventually iron toxicity.
Although pulmonary hypertension (PH) is a complication of thalassemia, the incidence of the condition 
is not clear, with studies suggesting an incidence rate of 10%-75% in patients with Beta-thalassemia 
major 2-4.  While the pathophysiology of PH in beta-thalassemia patients is not clearly known, iron 
overload and deposition in the lungs, liver and heart together with a past history of splenectomy have 
all been associated with PH 2,5,6. PH in such patients has been attributed to an increased response to 
vasoconstrictors as a result of an increased intracellular Ca2+ content secondary to potassium channel 
downregulation and endothelial injury in hypoxic conditions 2,7. 
Evidence also suggests that chronic haemolysis plays a key role in the development of pulmonary 
hypertension in B-thalassemia. The haemoglobin released from the broken down red blood cells 
somehow scavenges nitric oxide. Hence, the removal of nitric oxide and the lowering of its concentration 
in the blood reduces its vasodilatory effect on hypoxic pulmonary vasoconstriction. Also, following the 
breakdown of red blood cells, the enzyme arginase is released. This breaks down arginine – the substrate 
for the synthesis of nitrogen monoxide. Both of these mechanisms contribute to an overall decrease in 
NO levels, resulting in a relative increase in endothelin-1 which is a potent vasoconstrictor. Hence this 
imbalance leads to the development of pulmonary hypertension 8.
Risk factors: 
The risk factors which increase the probability that one develops this disease are mainly associated with 
genetic factors: Family history of thalassemia and certain ancestry.
Symptoms:
Beta Thalassemia Major is generally diagnosed at an early stage in infants of 6 to 24 months who fail to 
thrive and become pale together with possible enlargement of the liver and the spleen 1. Beta Thalassemia 
Major may be attributed to jaundice and pallor, growth retardation, skeletal changes, extramedullary 
haematopoiesis (with possible mass development), abdominal swelling and hepatosplenomegaly 1.
Cardiac complications which may include cardiomyopathy secondary to iron deposition and myocarditis 
also increase the morbidity and fatality rate of the condition 8. A significant contributor to such cardiogenic 
deaths in patients with Beta Thalassemia Major is the development of pulmonary hypertension, which is 
another complication of the condition 8.
Prevention:
Being a hereditary condition, the only method (so far) to prevent acquiring Beta Thalassemia is by 
population screening and genetic counselling. 
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Complications:
Together with the risks associated with Beta Thalassemia Major itself, the additional pulmonary 
hypertension may give rise to a number of complications 9. These include9:
• Right-sided heart failure (cor pulmonale)
       Due to increased resistance in the pulmonary circulation, the right ventricle enlarges so as to be able 
to generate enough force which would allow enough blood to be perfused to the lungs. However, 
the thickening of the walls and the enlargement of the right ventricular chamber has a limit, beyond 
which, right-sided heart failure occurs.
• Blood Clots
      The pulmonary hypertension increases the risk that one develops blood clots within the vessels of 
the lung. These further increase the resistance, and hence contribute to the pulmonary hypertension. 
Apart from this, another complication which may arise is that these blood clots may dislodge from 
the pulmonary vessels and end up in the general circulation where they may cause obstruction of 
other vessels.
• Arrhythmia
      Irregular heartbeats of all chambers of the heart are possible complications of pulmonary 
hypertension. The arrhythmias may lead to palpitations, dizziness or fainting and can be fatal.
• Bleeding
     This is another fatal complication of pulmonary hypertension, where one starts bleeding into the 
lungs and eventually coughing up blood – haemoptysis.
Treatment
Management of Beta Thalassemia Major mainly involves regular transfusions for the correction of 
the anaemia, suppression of erythropoiesis and inhibition of iron absorption from the gastrointestinal 
system (to decrease iron overload) together with treatment of iron overload which occurs frequently in 
patients on regular transfusion 1. The patients may therefore require the use of iron chelators and possible 
splenectomy while possible delayed puberty, hypogonadism and requirement of assisted reproduction 
should also be considered 1.
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